ArticleDermatology and therapy2026

A Response to "Letter to the Editor Regarding 'Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison'".

Sonja Ständer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.